Patients with EGFR mutations in both tumour samples and serum samples had a significantly longer median PFS than the patients without EGFR mutations (194 vs 55 days, P=0.016, in tumour samples; 174 vs 58 days, P=0.044, in serum samples; Figure 1A). The gene discussed is EGFR; the disease is neoplasm.